Ebola mAb114 vial

FREDERICK, Md. -- Just 48 hours after an Ebola clinical trial in the Democratic Republic of Congo (DRC) was stopped early because two therapies appeared to significantly reduce patients’ fatality rates, two Frederick National Laboratory staff members boarded a plane to help with the next step.

Meanwhile, the national laboratory’s Vaccine Clinical Materials Program (VCMP) sent a shipment of mAb114, one of the therapies, to the DRC.

Pages